Glenmark Pharmaceuticals Limited (GLENMARK) — FY26 Annual Report | 13 August 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Disclosure of email-registered shareholder notice for AGM and annual report access
💡 Investor Takeaway
Shareholders must verify their email registration to receive digital access to the AGM notice and annual report.

Glenmark Pharmaceuticals disclosed on August 13, 2026 that shareholders without registered email addresses will receive a notice with web links and QR codes to access the Integrated Annual Report and 48th AGM notice for FY 2025-26, as required under SEBI regulations. The company emphasized digital access to these documents via its website and CDN links.

📄 View Original Announcement (PDF)

About Glenmark Pharmaceuticals Limited (GLENMARK)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹68,205.11 Cr P/E: 37.9 ROE: 20.3% ROCE: 24.8% Div Yield: 0.10%

View full GLENMARK stock details →

📡 Get AI alerts when GLENMARK files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLENMARK — Free

📊 More GLENMARK filings

See all GLENMARK filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLENMARK files new disclosures

Track GLENMARK filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLENMARK — Free

Free account · 2 AI queries/day